Prostate cancer is the most common cancer in men, yet disparities persist in screening, diagnosis and treatment among populations with low socioeconomic status. Minority groups face barriers to clinical trial inclusion including limited awareness and financial challenges. Promoting diversity in clinical trials is crucial for inclusivity, improving treatment efficacy and achieving equitable health outcomes in prostate cancer care.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Powell, I. J. Epidemiology and pathophysiology of prostate cancer in African-American men. J. Urol. 177, 444–449 (2007).
Smedley, A. & Smedley, B. D. Race as biology is fiction, racism as a social problem is real: anthropological and historical perspectives on the social construction of race. Am. Psychol. 60, 16–26 (2005).
Riaz, I. B. et al. Disparities in the inclusion of racial and ethnic minority groups and older adults in prostate cancer clinical trials: a meta-analysis. JAMA Oncol. 9, 180–187 (2023).
Centers for Disease Control and Prevention. United States cancer statistics: prostate cancer incidence by stage at diagnosis. CDC https://www.cdc.gov/united-states-cancer-statistics/publications/prostate-cancer.html (2024).
Rencsok, E. M. et al. Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol. Biomarkers Prev. 29, 1374–1380 (2020).
National Academies of Sciences, Engineering, and Medicine. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups (National Academies Press, 2022).
US Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs (FDA, 2020).
Sekar, R. R., Herrel, L. A. & Stensland, K. D. Social determinants of health and the availability of cancer clinical trials in the United States. JAMA Netw. Open 7, e2410162 (2024).
Puri, D. et al. Striving for equity: examining health disparities in urologic oncology. Cancers 16, 3559 (2024).
McKay, R. R. et al. Tackling diversity in prostate cancer clinical trials: a report from the Diversity Working Group of the IRONMAN registry. JCO Glob. Oncol. 7, 495–505 (2021).
Kelsey, M. D. et al. Inclusion and diversity in clinical trials: actionable steps to drive lasting change. Contemp. Clin. Trials 116, 106740 (2022).
Gibson, D. et al. Evaluating the efficacy of ChatGPT as a patient education tool in prostate cancer: multimetric assessment. J. Med. Internet Res. 26, e55939 (2024).
Sibert, N. T. et al. Transforming a large-scale prostate cancer outcomes dataset to the OMOP common data model—experiences from a scientific data holder’s perspective. Cancers 16, 2069 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.V. reports receipt of funding from the National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, the US Office of Research Integrity and the Oklahoma Center for Advancement of Science and Technology, and internal grants from Oklahoma State University Center for Health Sciences — all outside of the present work. P.L. declares no competing interests.
Rights and permissions
About this article
Cite this article
Lang, P., Vassar, M. Addressing diversity barriers in prostate cancer clinical trials for equitable healthcare outcomes. Nat Rev Urol 22, 493–494 (2025). https://doi.org/10.1038/s41585-025-01008-8
Published:
Issue date:
DOI: https://doi.org/10.1038/s41585-025-01008-8
